ストックスクリーナーアプリを入手
4.43
4.73%
-0.22
アフターアワーズ：
4.43
前日終値:
$4.65
開ける：
$4.64
24時間の取引高:
3.85M
Relative Volume:
1.24
時価総額：
$709.51M
収益：
$181.41M
当期純損益:
$-59.56M
株価収益率:
-10.55
EPS:
-0.42
ネットキャッシュフロー:
$-38.83M
1週間 パフォーマンス:
-7.32%
1か月 パフォーマンス:
-5.94%
6か月 パフォーマンス:
+24.09%
1年 パフォーマンス:
+90.95%
1日の値動き範囲:
$4.305
$4.66
1週間の範囲:
$4.305
$5.105
52週間の値動き範囲:
$2.03
$6.07
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
名前
Xeris Biopharma Holdings Inc
セクター
電話
844-445-5704
住所
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
XERS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
4.43 | 765.54M | 181.41M | -59.56M | -38.83M | -0.42 |
|
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-11 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | 開始されました | Oppenheimer | Outperform |
| 2023-08-28 | 開始されました | Craig Hallum | Buy |
| 2022-10-21 | 開始されました | Jefferies | Buy |
| 2022-04-28 | 開始されました | Craig Hallum | Buy |
| 2021-11-17 | 開始されました | SVB Leerink | Outperform |
| 2021-10-29 | 開始されました | H.C. Wainwright | Buy |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2020-02-18 | 開始されました | Piper Sandler | Overweight |
| 2018-07-16 | 開始されました | Jefferies | Buy |
| 2018-07-16 | 開始されました | Leerink Partners | Outperform |
| 2018-07-16 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Xeris Biopharma Holdings Inc (XERS) 最新ニュース
Transcript : Xeris Biopharma Holdings, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 01 - marketscreener.com
Xeris at Jefferies Conference: Strategic Growth and Future Prospects By Investing.com - Investing.com Canada
xeris biopharma holds annual meeting, elects directors - Investing.com
Xeris Pharmaceuticals Holds 2025 Annual Stockholders Meeting - TipRanks
Xeris Biopharma touts ambitious growth plan, promising hypothyroidism drug - Crain's Chicago Business
Xeris Biopharma Holdings, Inc. Rings the Closing Bell - Nasdaq
Transcript : Xeris Biopharma Holdings, Inc.Analyst/Investor Day - marketscreener.com
Xeris Biopharma Holdings, Inc. Reaffirms Revenue Guidance for the Year 2025 - marketscreener.com
Xeris Biopharma projects $1 billion Recorlev revenue by 2035 - Investing.com India
Xeris Unveils Strategy for Long-Term Growth and Value Creation a - GuruFocus
Xeris Biopharma Holdings Reaffirms 2025 Revenue Guidance Of $260-$275 Million - marketscreener.com
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day - Yahoo Finance
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Holdings Lessened by Ameriprise Financial Inc. - Defense World
XERS: Key Highlights from Analyst and Investor Day | XERS Stock News - GuruFocus
ProShare Advisors LLC Cuts Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $273,000 Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Bank of America Corp DE Sells 17,544 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Deutsche Bank AG Grows Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Millennium Management LLC Raises Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
BNP Paribas Financial Markets Acquires Shares of 100,012 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma (NASDAQ:XERS) Cut to “Hold” at Wall Street Zen - Defense World
Northern Trust Corp Purchases 38,155 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma Holdings Inc (XERS) With A Potential Upside Of More Than 18.7% - Stocksregister
Jane Street Group LLC Decreases Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Announces Details for Analyst & Investor Day | XERS Stock News - GuruFocus
Xeris Announces Details for Analyst & Investor Day - Business Wire
Balyasny Asset Management L.P. Makes New Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
The Manufacturers Life Insurance Company Lowers Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Leerink Partnrs Estimates Xeris Biopharma Q2 Earnings - Defense World
Voya Investment Management LLC Reduces Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Raymond James Financial Inc. Purchases New Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Hsbc Holdings PLC Decreases Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Position Raised by Price T Rowe Associates Inc. MD - Defense World
Xeris Biopharma Holdings, Inc. (XERS): Among the Unstoppable Growth Stocks to Invest in Now - Yahoo Finance
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives $6.10 Consensus Target Price from Analysts - Defense World
Xeris Biopharma (NASDAQ:XERS) Stock Price Expected to Rise, Oppenheimer Analyst Says - Defense World
Xeris Biopharma Holdings First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2025 Earnings Call Transcript - Insider Monkey
Oppenheimer Increases Price Target for Xeris Biopharma (XERS) to $7 | XERS Stock News - GuruFocus
XERS: Oppenheimer Raises Price Target for Xeris Biopharma Holdings | XERS Stock News - GuruFocus
Xeris Biopharma: Q1 Earnings Snapshot - New Haven Register
Xeris Biopharma Reports Record First Quarter 2025 Financial Results - BioSpace
Xeris Biopharma Holdings Inc (XERS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Xeris Biopharma Holdings Inc (XERS) Q1 2025 Earnings Call Highli - GuruFocus
Xeris Biopharma Holdings Inc (XERS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Advancements - GuruFocus
Xeris Biopharma Reports Strong Q1 2025 Growth - TipRanks
Xeris Pharmaceuticals Reports Strong Earnings and Growth - TipRanks
Xeris Biopharma raises revenue guidance for 2025 to $260M-$275M amid strong Recorlev growth - MSN
Xeris Biopharma Holdings, Inc. SEC 10-Q Report - TradingView
Transcript : Xeris Biopharma Holdings, Inc., Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com
Xeris Biopharma Holdings Inc (XERS) 財務データ
収益
当期純利益
現金流量
EPS
0.00%
0.54%
大文字化:
|
ボリューム (24 時間):